Here are three things to know.
1. This brings Fidelity’s holdings in Cynata to about 10 percent.
2. Fidelity will get 4 million shares at $1.28 each, a 4.5 percent premium to Cynata’s closing price May 25.
3. Cynata’s proprietary Cymerus stem cell platform technology enables the company to manufacture mesenchymal stem cells on a commercial scale.
More articles on biologics:
The global spine biologics market to grow at CAGR of 4.1% through 2022: 3 things to know
DiscGenics treats 1st patient in degenerative disc disease clinical trial: 5 things to know
3 things to know about Organogenesis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
